The viral immunotherapy delivers a replication-defective herpes simplex virus thymidine kinase gene and was administered in ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

"There was a bit of confidence in our group when they only got 200 [203], thinking we've dragged them back here," Hopes said ...

A comprehensive search of electronic databases was conducted up to 6 September 2024 to identify randomised controlled trials ...

Amgen today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall ...

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant ...

A new analysis published late last week in Vaccine concludes that COVID-19 vaccination averted 12,806 COVID-19 deaths among ...

Phase III data presented at ASCO 2025 and published in The New England Journal of Medicine show that Pfizer’s Braftovi (encorafenib), combined with Erbitux (cetuximab) and mFOLFOX6, significantly ...

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement ...

Johnson & Johnson announced today new data from a Phase 1 study evaluating pasritamig (JNJ-78278343), a first-in-class bispecific antibody that activates T-cells to harness the body's immune system ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

This isn’t some far-flung fantasy—it’s High Bridge Trail State Park in Rice, Virginia, and somehow it’s flying under the radar of even the most dedicated Old Dominion explorers. Let me tell you ...